Summary of findings 2: PLD alone vs other conventional chemotherapy: Hand‐foot syndrome (grade ≥ 3)
It is very uncertain whether summary of findings 2: PLD alone changes hand‐foot syndrome (grade ≥ 3) compared with other conventional chemotherapy (very low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Summary of findings 2: PLD alone vs other conventional chemotherapy Hand‐foot syndrome (grade ≥ 3) · adult women with recurrent platinum‐resistant EOC It is very uncertain whether summary of findings 2: PLD alone changes hand‐foot syndrome (grade ≥ 3) compared with other conventional chemotherapy (very low certainty). Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane Headline outcomes only | no estimate extracted | 6 studies · 2184 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.